InvestorsHub Logo
Followers 30
Posts 2792
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Thursday, 06/01/2023 1:09:12 PM

Thursday, June 01, 2023 1:09:12 PM

Post# of 381
(OT): The latest license is to Replay Bio and includes the entirety of the US NCI shared neoantigen library for allogeneic TCR-NKs https://www.federalregister.gov/documents/2022/12/30/2022-28404/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-natural-killer

Dr. Rezvani from MDA previously partnered with Takeda for CAR-NK. Now Replay Bio and MDA have created Syena for TCR-NK. Their first target for NY-ESO-1 should be in the clinic soon. Replay was on this podcast where they lay out their strategy https://www.labiotech.eu/trends-news/beyond-biotech-podcast-35-rare-disease-day/

Interesting that the CMO of AZN joined their board this week. Dr. June is on their SAB of course.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News